RELATED APPLICATIONSThis application is a continuation of co-pending U.S. patent application Ser. No. 09/090,794, filed Jun. 4, 1998, which is a continuation-in-part of U.S. patent application Ser. No. 09/032,367, filed Feb. 27, 1998 (now U.S. Pat. No. 6,044,846) and a continuation-in-part of U.S. patent application Ser. No. 09/921,356, filed Aug. 2, 2001, which is a continuation of U.S. patent application Ser. No. 09/032,366, filed Feb. 27, 1998 (now abandoned).[0001]
FIELD OF THE INVENTIONThis invention relates generally to an apparatus to treat sphincters, and more particularly to an apparatus to treat esophageal sphincters.[0002]
DESCRIPTION OF RELATED ARTGastroesophageal reflux disease (GERD) is a common gastroesophageal disorder in which the stomach contents are ejected into the lower esophagus due to a dysfunction of the lower esophageal sphincter (LES). These contents are highly acidic and potentially injurious to the esophagus resulting in a number of possible complications of varying medical severity. The reported incidence of GERD in the U.S. is as high as 10% of the population (Castell D O; Johnston B T:[0003]Gastroesophageal Reflux Disease: Current Strategies For Patient Management. Arch Fam Med,5(4):221-7; (April 1996)).
Acute symptoms of GERD include heartburn, pulmonary disorders and chest pain. On a chronic basis, GERD subjects the esophagus to ulcer formation, or esophagitis and may result in more severe complications including esophageal obstruction, significant blood loss and perforation of the esophagus. Severe esophageal ulcerations occur in 20-30% of patients over age 65. Moreover, GERD causes adenocarcinoma, or cancer of the esophagus, which is increasing in incidence faster than any other cancer (Reynolds J C:[0004]Influence Of Pathophysiology, Severity, And Cost On The Medical Management Of Gastroesophageal Reflux Disease.Am J Health Syst Pharm, 53(22 Suppl 3):S5-12 (Nov. 15, 1996)).
Current drug therapy for GERD includes histamine receptor blockers which reduce stomach acid secretion and other drugs which may completely block stomach acid. However, while pharmacologic agents may provide short term relief, they do not address the underlying cause of LES dysfunction.[0005]
Invasive procedures requiring percutaneous introduction of instrumentation into the abdomen exist for the surgical correction of GERD. One such procedure, Nissen fundoplication, involves constructing a new “valve” to support the LES by wrapping the gastric fundus around the lower esophagus. Although the operation has a high rate of success, it is an open abdominal procedure with the usual risks of abdominal surgery including: postoperative infection, herniation at the operative site, internal hemorrhage and perforation of the esophagus or of the cardia. In fact, a recent 10 year, 344 patient study reported the morbidity rate for this procedure to be 17% and[0006]mortality 1% (Urschel, J D:Complications Of Antireflux Surgery,Am J Surg 166(1): 68-70; (July 1993)). This rate of complication drives up both the medical cost and convalescence period for the procedure and may exclude portions of certain patient populations (e.g., the elderly and immuno-compromised).
Efforts to perform Nissen fundoplication by less invasive techniques have resulted in the development of laparoscopic Nissen fundoplication. Laparoscopic Nissen fundoplication, reported by Dallemagne et al.[0007]Surgical Laparoscopy and Endoscopy,Vol. 1, No. 3, (1991), pp. 138-43 and by Hindler et al.Surgical Laparoscopy and Endoscopy,Vol. 2, No. 3, (1992), pp. 265-272, involves essentially the same steps as Nissen fundoplication with the exception that surgical manipulation is performed through a plurality of surgical cannula introduced using trocars inserted at various positions in the abdomen.
Another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,088,979. In this procedure, an invagination device containing a plurality of needles is inserted transorally into the esophagus with the needles in a retracted position. The needles are extended to engage the esophagus and fold the attached esophagus beyond the gastroesophageal junction. A remotely operated stapling device, introduced percutaneously through an operating channel in the stomach wall, is actuated to fasten the invaginated gastroesophageal junction to the surrounding involuted stomach wall.[0008]
Yet another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,676,674. In this procedure, invagination is done by a jaw-like device and fastening of the invaginated gastroesophageal junction to the fundus of the stomach is done via a transoral approach using a remotely operated fastening device, eliminating the need for an abdominal incision. However, this procedure is still traumatic to the LES and presents the postoperative risks of gastroesophageal leaks, infection and foreign body reaction, the latter two sequela resulting when foreign materials such as surgical staples are implanted in the body.[0009]
While the methods reported above are less invasive than an open Nissen fundoplication, some still involve making an incision into the abdomen and hence the increased morbidity and mortality risks and convalescence period associated with abdominal surgery. Others incur the increased risk of infection associated with placing foreign materials into the body. All involve trauma to the LES and the risk of leaks developing at the newly created gastroesophageal junction.[0010]
Besides the LES, there are other sphincters in the body which if not functioning properly can cause disease states or otherwise adversely affect the lifestyle of the patient. Reduced muscle tone or otherwise aberrant relaxation of sphincters can result in a laxity of tightness disease states including but not limited to urinary incontinence.[0011]
There is a need to provide an apparatus to remodel a sphincter. Another need exists for an apparatus to deliver a polymer material into a sphincter wall and deliver sufficient energy to the polymer material to increase a wall thickness of the sphincter. There is a further need for an apparatus to controllably reduce a diameter of a sphincter without creating a permanent impairment of the sphincter's ability to achieve a physiologically normal state of closure. Still a further need exists for an apparatus to deliver energy to a sphincter wall and create a tightening of a sphincter without permanently damaging anatomical structures near the sphincter. There is still another need for an apparatus to reduce the diameter of a lower esophageal sphincter to reduce a frequency of reflux of stomach contents into an esophagus.[0012]
SUMMARY OF THE INVENTIONOne aspect of the invention provides a method for treating a sphincter. The method provides a polymer material having a liquid state. The method also provides a catheter having a distal end, a tissue piercing device carried by the distal end, and an energy delivery device coupled to the tissue piercing device. The tissue piercing device has a lumen. The method introduces the catheter into an esophagus and pierces an exterior sphincter tissue surface within with the tissue piercing device. The method advances the tissue piercing device into an interior sphincter tissue site and conveys the polymer material while in a liquid state through the lumen into the interior sphincter tissue site. The method delivers energy to the tissue piercing device to transform the polymer material into a less liquid state within the interior sphincter tissue site, to thereby remodel the sphincter.[0013]
In one embodiment, the method delivers energy to the tissue piercing device to create controlled cell necrosis in the sphincter.[0014]
In one embodiment, the method provides a cooling medium and conveys the cooling medium into contact with the exterior sphincter tissue surface pierced by the tissue piercing device.[0015]
The polymer material can comprise, e.g., collagen or silicone.[0016]
BRIEF DESCRIPTION OF THE DRAWINGSFIG. 1A is an illustrated lateral view of the upper GI tract illustrating the positioning of the sphincter treatment apparatus of the present invention in the lower esophageal sphincter.[0017]
FIG. 1B is an illustrated lateral view of the upper GI tract illustrating the delivery of a polymer material into a treatment site in the sphincter wall.[0018]
FIG. 2 is a lateral view of the present invention illustrating the catheter lumen, catheter end energy delivery device, cable and power supply.[0019]
FIG. 3 depicts a cross sectional view of sphincter anatomy illustrating the layers of the sphincter wall.[0020]
FIG. 4A is a lateral view of the RF electrode and sphincter wall, illustrating insulated and exposed electrode segments and the creation of a protected site.[0021]
FIG. 4B is a lateral view of the RF electrode and sphincter wall, illustrating apertures in the catheter which are used to control the penetration angle of the tissue piercing device in a sphincter wall.[0022]
FIG. 5 is an enlarged lateral view illustrating the placement of sensors on/adjacent the energy delivery device/RF electrode.[0023]
FIG. 6 is a cross sectional view illustrating the use of a fluid introduction lumen and aperture in the energy delivery device/RF electrode for delivery of a cooling medium.[0024]
FIG. 7 is a cross sectional view illustrating a visualization device coupled to an embodiment of the invention.[0025]
FIG. 8 is a lateral view of the sphincter wall illustrating the use of cooling medium to create cooled zones at the electrode-tissue interface.[0026]
FIG. 9 depicts the flow path and fluid connections employed to deliver cooling medium to the energy delivery device/RF electrode and/or electrode-tissue interface.[0027]
FIG. 10 is a flow chart illustrating a sphincter treatment method.[0028]
FIG. 11 is a lateral view of sphincter smooth muscle tissue illustrating electrical foci and electrically conductive pathways for the origination and conduction of aberrant electrical signals in the smooth muscle of the lower esophageal sphincter or other tissue.[0029]
FIG. 12 is a lateral view of a sphincter wall illustrating the infiltration of tissue healing cells into a lesion in the smooth tissue of a sphincter following treatment with the sphincter treatment apparatus of the present invention.[0030]
FIG. 13 is a view similar to that of FIG. 12 illustrating shrinkage of the lesion site caused by cell infiltration.[0031]
FIG. 14 is a lateral view of the esophageal wall illustrating the preferred placement of lesions in the smooth muscle layer of an esophageal sphincter.[0032]
FIG. 15 is a lateral view illustrating a radial distribution of cured polymer particles used to increase sphincter wall thickness and decrease sphincter inner diameter.[0033]
FIG. 16 is a lateral view illustrating the use of a band of shrunk collagen surrounding and mechanically supporting a radial distribution of cured polymer particles.[0034]
FIG. 17 depicts a block diagram of the feed back control system that can be used with the sphincter treatment apparatus.[0035]
FIG. 18 depicts a block diagram of an analog amplifier, analog multiplexer and microprocessor used with the feedback control system of FIG. 17.[0036]
FIG. 19 depicts a block diagram of the operations performed in the feedback control system depicted in FIG. 17.[0037]
DETAILED DESCRIPTIONReferring now to FIGS. 1A, 1B and[0038]2, one embodiment of asphincter treatment apparatus10 delivers energy to atarget tissue site12, also calledtreatment site12, to producecell necrosis14 in asphincter16, such as the lower esophageal sphincter (LES). In this embodiment,sphincter treatment apparatus10 comprises a flexibleelongate shaft18, also calledintroducer18, orcatheter18, with adistal extremity20, also calledcatheter end20, in turn coupled with one or moreenergy delivery devices22.Energy delivery devices22 are coupled to aguide wire24 also calledcable24 and are also configured to be coupled to a power source.Energy delivery device22 is coupled to atissue piercing device26, which can also be thedistal end26 ofenergy delivery device22.Energy delivery device22 andtissue piercing device26 may both have a continuous internal lumen23 that is fluidically coupled to afluid lumen24′ inguide wire24.Energy delivery device22 andtissue piercing device26 are configured to penetrate a fixed depth into asphincter wall28 and deliver energy to a portion thereof. In one embodimenttissue piercing device26 is a hollowhypodermic needle26 well known to those skilled in the art.
In one embodiment illustrated in FIG. 1B,[0039]tissue piercing device26 is configured to penetrate a fixed depth into asphincter wall28 and deliver a polymer material15 (also called polymer15) via lumen23 to atreatment site12. Delivery of polymer15 can be accomplished using an infusion pump or syringe (neither shown but both well known to those skilled in the art) fluidically coupled totissue piercing device26. Upon delivery of sufficient thermal energy fromenergy delivery device22 totreatment site12, the delivered polymer material15′, undergoes a curing and/or polymerization reaction well known to those skilled in the art whereby one or more of the following occurs: (i) crosslinks form between adjacent molecular chains of polymer15, (ii) the molecular chains of polymer15 contract along their linear/longitudinal axis resulting in a shortening or shrinkage of polymer15 in one or more axises, (iii) the molecular chains of polymer15 increase in length (iv) a viscoelastic property of delivered polymer15 is altered (v) the viscosity of delivered polymer15′ is increased, and (vi) the stiffness of delivered polymer15 is increased. As a result of one or more of these changes, all or a portion of delivered polymer15′ may undergo a transformation from a liquid or emulsion state to a less liquid or semisolid state. The portion of delivered polymer15′ that undergoes this reaction is called cured polymer15″ also called polymer particle15″. Suitable materials for polymer15 include polysiloxanes (e.g. silicones), polyurethanes and collagen, all well known to those skilled in the art. Suitable geometries for polymer particle15″ include, but are not limited to, the following shapes: spherical, semispherical, oval and cylindrical. Suitable diameters for polymer particles15″ include a range from 0.01 to 0.5 inches.
Referring to FIG. 2,[0040]catheter end20 is configured to be positionable in asphincter16 such as the LES or adjacent anatomical structure, such as the cardia of the stomach.Catheter18 has sufficient length to positioncatheter end20 in the LES and/or stomach using a trans-oral approach. Typical lengths forcatheter18 include, but are not limited to, a range of 40-180 cms. Suitable materials forcatheter18 include, but are not limited to, polyethylenes, polyurethanes, silicones and other biocompatible polymers known to those skilled in the art.Energy delivery devices22 can be in the form of needle electrodes, both solid or hollow, as is well known to those skilled in the art. In other embodiments,energy delivery device22 can be conical, cylindrical, rectangular or any polyhedron; each of said shapes having a flat, rounded, beveled, or pointed tip. Suitable materials forenergy delivery device22 include a combination of one or more of the following: i) stainless and other steels suitable for electrode applications known to those skilled in the art, ii) alloys of gold, silver and platinum, iii) nickel-titanium alloys, or iv) other conductors known to those skilled in the art.
[0041]Catheter18 may have one ormore lumens30, that extend the frill length ofcatheter18, or only a portion thereof.Lumens30 may be used as paths for cables, catheters, guide wires, pull wires, insulated wires, fluid and optical fibers.Lumens30 may have one ormore apertures30′ at or neardistal catheter end20. In one embodiment, lumens30 (along withaperture30′) incatheter18 are used as a guiding pathway forguidewire24 to facilitate the positioning oftissue piercing device26 attreatment site12.
[0042]Guide wire24 is configured to facilitate the positioning of energy delivery device22 a selectable distance (1-4 mms) into thesphincter wall28. Suitable materials and components forguide wire24 include an insulated wire, an insulated guide wire, a plastic-coated stainless steel hypotube with internal wiring, or a catheter with internal wiring, all of which are known to those skilled in the art.Guide wire24 may also have one ormore lumens24′ which can be used to deliver fluid or gas. Also guidewire24 may have one or moreproximal fittings24″ (such as a luer fitting or lemo connector) for facilitating connection to fluid lines and electronic cabling.
Turning now to a discussion of energy-tissue interactions, energy flowing through sphincter or other tissue causes heating of the tissue due to absorption of the energy by the tissue. This heating can cause injury to the affected cells and can be substantial enough to cause cell death, a phenomenon also known as cell necrosis. The controlled delivery of energy by[0043]energy delivery device22 results in controlledcell necrosis14, also calledlesions14, attarget tissue site12.
Suitable energy devices and power sources for[0044]energy delivery device22 include the following: (i) a radio-frequency (RF) source coupled to an RF electrode, (ii) a coherent source of light coupled to an optical fiber, (iii) an incoherent light source coupled to an optical fiber, (iv) a heated fluid coupled to a catheter with a closed channel configured to receive the heated fluid, (v) a heated fluid coupled to a catheter with an open channel configured to receive the heated fluid, (vi) a cooled fluid coupled to a catheter with a closed channel configured to receive the cooled fluid, (vii) a cooled fluid coupled to a catheter with an open channel configured to receive the cooled fluid, (viii) a cryogenic fluid, (ix) a resistive heating source, (x) a microwave source providing energy from 915 MHz to 2.45 GHz and coupled to a microwave antenna, (xi) an ultrasound power source coupled to an ultrasound emitter, wherein the ultrasound power source produces energy in the range of 300 KHZ to 3 GHz, or (xii) combinations of any of the above. For ease of discussion for the remainder of this application, the power source utilized is an RF source andenergy delivery device22 is one ormore RF electrodes22, also described aselectrodes22. However, all of the other herein mentioned power sources and energy delivery devices are equally applicable tosphincter treatment apparatus10.
Turning now to a discussion of sphincter anatomy (depicted in FIG. 3), the first several layers of[0045]sphincter16 consist of amucosal layer32, asubmucosal layer33 and an underlying smooth musclecollagen tissue layer34.RF electrode22 is configured to produce controlled cell necrosis orlesions14 in smooth musclecollagen tissue layer34 underlying mucosal andsubmucosal layers32 and33. More specifically,RF electrode22 is configured to produce controlledcell necrosis14 in the portion of smoothmuscle collagen tissue34′ that lies approximately1-4 nuns from the surface ofmucosal layer32.
Referring now to FIG. 4A,[0046]RF electrode22 has an insulator36, covering the exterior of aninsulated segment38 except for an exposedsegment40. For purposes of this disclosure, an insulator is a barrier to either thermal or electromagnetic energy flow. As shown in FIG. 4A,insulated segment38 is of sufficient length to extend intosphincter wall28 and minimize the transmission of energy and subsequent injury to a protectedsite42 near or adjacent toinsulated segment38. Typical lengths forinsulated segment38 include, but are not limited to, 1-4 mms. Suitable materials for insulator36 include, but are not limited to, polytetrafluoroethylene (Teflon®, polyimides, polyamides and other insulating polymers known to those skilled in the art.
Referring now to FIG. 4B, in one[0047]embodiment lumens30 andapertures30′ are of sufficient diameter to allow the free movement ofguidewire24 incatheter18 so as to be able to controllably positiontissue piercing device26 to a selected depth intosphincter wall28.Apertures30′ can be configured so as to control the angle of penetration48 (also calledpenetration angle48 or emergence angle48) thattissue piercing device26 makes withsphincter wall28.Apertures30′ can be further configured so as to maintainpenetration angle48 constant (or near constant) during the insertion oftissue piercing device26 intosphincter wall28 so as to minimize tearing or unnecessary trauma to sphincter wall tissue. In various embodiments, theemergence angle48 ofapertures30′ which can vary from 1 to 90°.
Referring now to FIG. 5, one or[0048]more sensors44 can be coupled toRF electrode22 for sensing the temperature of sphincter tissue attarget tissue site12. More specifically,sensors44 permit accurate determination of the surface temperature ofsphincter wall28 at anelectrode tissue interface46. This information can be used to regulate both the delivery of energy and cooling medium to the interior surface ofsphincter wall28 as will be discussed herein.Sensors44 can be positioned on or adjacent toRF electrode22. Suitable sensors that may be used forsensor44 include: thermocouples, fiber optics, resistive wires, thermocouple IR detectors, and the like. Suitable thermocouples forsensor44 include: T type with copper constantene, J type, E type and K types as are well known those skilled in the art.
Referring now to FIG. 6,[0049]RF electrode22 includes a fluid introduction lumen23, that may be coupled withcatheter lumen30. These coupled lumens provide a path for the delivery of a fluid, such as a cooling or electrolytic fluid (which will be discussed herein), toelectrode tissue interface46 or another site. As shown in FIG. 6, fluid introduction lumen23 may include anaperture50 on the distal portion ofRF electrode22.
Referring now to FIG. 7, another embodiment of[0050]sphincter treatment apparatus10 includes avisualization device52 which can include a combination of one or more of the following: a viewing scope, an expanded eyepiece, fiber optics (both imaging and illuminating fibers), video imaging and the like.
It may be desirable to employ a[0051]cooling system54 coupled toenergy delivery device22 to cool all or a portion of energy-delivery device22 and the area nearelectrode tissue interface46 before, during or after the delivery of energy in order to reduce the degree and area of cell injury in the tissue adjacentelectrode tissue interface46. As shown in FIG. 8, the use of cooling protects against, or otherwise reduces the degree of, cell damage to cooledzone56 in the vicinity ofaperture50 and/orelectrode tissue interface46 which will preferably include mucosal andsubmucosal layers32 and33. In one embodiment shown in FIG. 9,cooling system54 can include one or more of the following: i) a cooling medium55 (which can be a liquid or a gas) that is delivered toRF electrode22 viaaperture50 and flow-controlled via afeedback control system60 discussed herein, ii) acooling medium reservoir58 coupled toaperture50, and iii) a cooling device59 (which may be integral to fluid reservoir58) coupled to coolingmedium55 and controlled via afeedback control system60 discussed herein. In another embodiment, coolingmedium55 can be introduced viaapertures50 or semipermeable membranes located in one or more locations onsphincter treatment apparatus10 in communication withreservoir58 and thermal communication withcooling device59. In yet another embodiment, coolingmedium55 can be introduced externally toRF electrode22. In still another embodiment, coolingmedium55 is thermally coupled toRF electrode22 and/orelectrode tissue interface46. In yet another embodiment, cooling device59 (such as a Peltier effect device or heat pipe) is thermally coupled toRF electrode22 and/orelectrode tissue interface46.
FIG. 10 is a flow chart illustrating a method for using[0052]sphincter treatment apparatus10. In this embodiment,sphincter treatment apparatus10 is first introduced into the esophagus under local anesthesia and positioned attarget tissue site12.Sphincter treatment apparatus10 can be introduced into the esophagus by itself or through a lumen in an endoscope (not shown), such as disclosed in U.S. Pat. Nos. 5,448,990 and 5,275,608, incorporated herein by reference, or a similar esophageal access device known to those skilled in the art.
The diagnostic phase of the procedure then begins and can be performed using a variety of diagnostic methods, including, but not limited to, the following: (i) visualization of the interior surface of the esophagus via an endoscope or other viewing apparatus inserted into the esophagus, (ii) visualization of the interior morphology of the esophageal wall using ultrasonography to establish a baseline for the tissue to be treated, (iii) impedance measurement to determine the electrical conductivity between the esophageal mucosal layers and[0053]sphincter treatment apparatus10, and (iv) measurement and surface mapping of the electropotential of the LES during varying time periods which may include such events as depolarization, contraction and repolarization of LES smooth muscle tissue. This latter technique is done to determinetarget tissue sites12 in the LES or adjoining anatomical structures that are acting aselectrical foci107 or electricallyconductive pathways109 for abnormal or inappropriate polarization and relaxation of the smooth muscle of the LES (Refer to FIG. 11).
After diagnosis, the treatment phase of the procedure then begins. In this phase of the procedure the delivery of energy to target[0054]tissue site12 can be conducted under feedback control (described herein), manually or by a combination of both. Feedback control enablessphincter treatment apparatus10 to be positioned and retained in the esophagus during treatment with minimal attention by the physician. Feedback can be included and is achieved by the use of one or more of the following methods: (i) visualization, (ii) impedance measurement, (iii) ultrasonography, (iv) temperature measurement and, (v) sphincter contractile force measurement via manometry. A second diagnostic phase may be included after the treatment is completed. This provides an indication of LES tightening treatment success, and whether or not a second phase of treatment, to all or only a portion of the esophagus, now or at some later time, should be conducted. The second diagnostic phase is accomplished through, (i) visualization, (ii) measuring impedance, (iii) ultrasonography, (iv) temperature measurement, or (v) measurement of LES tension and contractile force via manometry. It will be appreciated that the above procedure is applicable in whole or part to the treatment of other sphincters in the body.
The area and magnitude of cell injury in the LES or[0055]sphincter16 can vary. However, it is desirable to deliver sufficient energy to the targetedtissue site12 to be able to achieve tissue temperatures in the range of 55-95° C. and producelesions14 at depths ranging from 1-4 mms from the interior surface of the LES orsphincter wall28. It is also desirable to deliver sufficient energy such that the resultinglesions14 have a sufficient magnitude and area of cell injury to cause an infiltration and/or proliferation oflesion14 byfibroblasts110,myofibroblasts112,macrophages114 and other cells involved in the tissue healing process (refer to FIG. 12). As shown in FIG. 13, these cells cause a contraction of tissue aroundlesion14, decreasing its volume and/or altering the biomechanical properties atlesion14 so as to result in a tightening of LES orsphincter16. These changes are reflected in transformedlesion14′ shown in FIG. 13.
It is desirable that[0056]lesions14 are predominantly located in the smooth muscle collagen layer of selectedsphincter16 at the depths ranging from 1 to 4 mms from the interior surface ofsphincter wall28.
Accordingly, the diameter of[0057]lesions14 can vary between 0.1 to 4 mms. It is preferable thatlesions14 are less than 4 mms in diameter in order to reduce the risk of thermal damage to the mucosal layer. In one embodiment, a 2mm diameter lesion14 centered in the wall of the smooth muscle collagen layer provides a 1 mm buffer zone to prevent damage to the mucosa, submucosa and adventitia, while still allowing for cell infiltration and subsequent sphincter tightening on approximately 50% of the thickness of the wall of the smooth muscle collagen layer (refer to FIG. 14). Also,lesions14 can vary both in number and position withinsphincter wall28. Once treatment is completed,sphincter treatment apparatus10 is withdrawn from the esophagus orother sphincter16. This results in the LES or other sphincter returning to approximately its pretreatment state and diameter.
Referring now to FIG. 15, in one embodiment polymer particles[0058]15″ can be distributed in a variety of patterns insphincter wall28 including a radial distribution at even depths along a radial axis ofsphincter16. Other distributions not shown include: (i) a wavy or folded circle of polymer particles15″ at varying depths insphincter wall28 evenly spaced along the radial axis ofsphincter16, (ii) polymer particles15″ randomly distributed at varying depths, but evenly spaced in a radial direction; and, (iii) an eccentric pattern of polymer particles15″ in one or more radial locations insphincter wall28. The pattern of and diameter of polymer particles15″ can be selected to controllably increase thethickness28′ ofsphincter wall28 and/or decrease theinner diameter16′ ofsphincter16.
Referring now to FIG. 16, RF energy can be delivered to[0059]sphincter wall28 to shrink native collagen51 within the smooth musclecollagen tissue layer34 ofsphincter wall28 so as to create a supporting band57 of tightened collagen in contact with one or more of polymer particles15″ distributed along a radial axis ofsphincter16. Band57 serves to both mechanically link and mechanically support polymer particles15″. This serves one or more of-the following functions: (i) distribution of the stresses withinsphincter wall28, (ii) retention of the desired placement of polymer particles15″ withinsphincter wall28; and, (iii) maintenance of improvements in the tension and inner diameter ofsphincter wall28. Also band57 can be selectively shrunk so as to selectively tightensphincter16 and decreaseinner sphincter diameter16′. In another embodiment, band57 can be composed offibroblasts110,myofibroblasts112 and other tissue healing cells.
In one embodiment, elements of[0060]sphincter treatment apparatus10 are coupled to an open or closed loopfeedback control system60. Referring now to FIG. 17, an open or closedloop feedback system60couples sensor346 toenergy source392. In this embodiment,electrode314 is one ormore RF electrodes314. The temperature of the tissue, or ofRF electrode314, is monitored, and the output power ofenergy source392 adjusted accordingly. The physician can, if desired, override the closed oropen loop system60. Amicroprocessor394 can be included and incorporated in the closed or open loop system to switch power on and off, as well as modulate the power. Theclosed loop system60 utilizesmicroprocessor394 to serve as a controller, monitor the temperature, adjust the RF power, analyze the result, refeed the result, and then modulate the power.
With the use of[0061]sensor346 andfeedback control system60, tissue adjacent toRF electrode314 can be maintained at a desired temperature for a selected period of time without causing a shut down of the power circuit to electrode314 due to the development of excessive electrical impedance atelectrode314 or adjacent tissue as is discussed herein. EachRF electrode314 is connected to resources which generate an independent output. The output maintains a selected energy atRF electrode314 for a selected length of time.
Current delivered through[0062]RF electrode314 is measured bycurrent sensor396. Voltage is measured byvoltage sensor398. Impedance and power are then calculated at power andimpedance calculation device400. These values can then be displayed at user interface anddisplay402. Signals representative of power and impedance values are received by acontroller404.
A control signal is generated by[0063]controller404 that is proportional to the difference between an actual measured value, and a desired value. The control signal is used bypower circuits406 to adjust the power output an appropriate amount in order to maintain the desired power delivered atrespective RF electrodes314.
In a similar manner, temperatures detected at[0064]sensor346 provide feedback for maintaining a selected power. Temperature atsensor346 is used as a safety means to interrupt the delivery of power when maximum pre-set temperatures are exceeded. The actual temperatures are measured attemperature measurement device408, and the temperatures are displayed at user interface anddisplay402. A control signal is generated bycontroller404 that is proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used bypower circuits406 to adjust the power output an appropriate amount in order to maintain the desired temperature delivered at thesensor346. A multiplexer can be included to measure current, voltage and temperature, at thesensor346, and energy can be delivered toRF electrode314 in monopolar or bipolar fashion.
[0065]Controller404 can be a digital or analog controller, or a computer with software. Whencontroller404 is a computer it can include a CPU coupled through a system bus. This system can include a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in the art. Also coupled to the bus is a program memory and a data memory.
User interface and[0066]display402 includes operator controls and a display.Controller404 can be coupled to imaging systems including, but not limited to, ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like. Further, direct visualization and tactile imaging can be utilized. The output ofcurrent sensor396 andvoltage sensor398 are used bycontroller404 to maintain a selected power level atRF electrode314. The amount of RF energy delivered controls the amount of power. A profile of the power delivered toelectrode314 can be incorporated incontroller404 and a preset amount of energy to be delivered may also be profiled.
Circuitry, software and feedback to[0067]controller404 result in process control, the maintenance of the selected power setting which is independent of changes in voltage or current, and is used to change the following process variables: (i) the selected power setting, (ii) the duty cycle (e.g., on-off time), (iii) bipolar or monopolar energy delivery; and, (iv) fluid delivery, including flow rate and pressure. These process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored atsensor346.
Referring now to FIG. 18,[0068]current sensor396 andvoltage sensor398 are connected to the input of ananalog amplifier410.Analog amplifier410 can be a conventional differential amplifier circuit for use withsensor346. The output ofanalog amplifier410 is sequentially connected by ananalog multiplexer412 to the input of A/D converter414. The output ofanalog amplifier410 is a voltage which represents the respective sensed temperatures. Digitized amplifier output voltages are supplied by A/D converter414 tomicroprocessor394.Microprocessor394 may be a type 68HCII available from Motorola. However, it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to calculate impedance or temperature.
[0069]Microprocessor394 sequentially receives and stores digital representations of impedance and temperature. Each digital value received bymicroprocessor394 corresponds to different temperatures and impedances.
Calculated power and impedance values can be indicated on user interface and[0070]display402. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared bymicroprocessor394 to power and impedance limits. When the values exceed predetermined power or impedance values, a warning can be given on user interface anddisplay402, and additionally, the delivery of RF energy can be reduced, modified or interrupted. A control signal frommicroprocessor394 can modify the power level supplied byenergy source392.
FIG. 19 illustrates a block diagram of a temperature and impedance feedback system that can be used to control the delivery of energy to[0071]tissue site416 byenergy source392 and the delivery of cooling medium55 toelectrode314 and/ortissue site416 byflow regulator418. Energy is delivered toRF electrode314 byenergy source392, and applied totissue site416. Amonitor420 ascertains tissue impedance, based on the energy delivered to tissue, and compares the measured impedance value to a set value. If measured impedance is within acceptable limits, energy continues to be applied to the tissue. However if the measured impedance exceeds the set value, a disablingsignal422 is transmitted toenergy source392, ceasing further delivery of energy toRF electrode314.
The control of cooling medium[0072]55 toelectrode314 and/ortissue site416 is done in the following manner. During the application of energy,temperature measurement device408 measures the temperature oftissue site416 and/orRF electrode314. Acomparator424 receives a signal representative of the measured temperature and compares this value to a pre-set signal representative of the desired temperature. If the measured temperature has not exceeded the desired temperature,comparator424 sends a signal to flowregulator418 to maintain the cooling solution flow rate at its existing level. However if the tissue temperature is too high,comparator424 sends a signal to a flow regulator418 (connected to an electronically controlled micropump, not shown) representing a need for an increased cooling solution flow rate.
The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be defined by the following claims and their equivalents.[0073]